Is SGMO or SLXN more undervalued in 2026?

CirclFi compares Sangamo Therapeutics, Inc. (SGMO) and Silexion Therapeutics Corp (SLXN) using 13 institutional-grade valuation models. SGMO has a Quality of Company score of 5.2/10 while SLXN scores 5.3/10.

Which is a better buy — SGMO or SLXN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SGMO and SLXN valuations compare?

SGMO at $0.22 and SLXN at $4.91 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SGMO vs SLXN Valuation Comparison 2026 — Intrinsic Value Analysis

SGMO

Biological Products, (No Diagnostic Substances)

Sangamo Therapeutics, Inc.

Quality

5.2

out of 10

Value Trap

LOW

Price

$0.22

Last close

Models

9/13

Active

SLXN

Biological Products, (No Diagnostic Substances)

Silexion Therapeutics Corp

Quality

5.3

out of 10

Value Trap

SAFE

Price

$4.91

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	SGMO Fair Value	SGMO Upside	SLXN Fair Value	SLXN Upside
Bayesian DCF	Intrinsic	$0.03	-84.2%	$0.41	-91.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.46	+110.9%	$1.55	-68.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SGMO vs SLXN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SGMO vs SLXN — Which Stock Is More Undervalued?

SLXN scores higher with a 5.3/10 quality rating vs SGMO's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Sangamo Therapeutics, Inc. (SGMO) and Silexion Therapeutics Corp (SLXN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SGMO currently trades at $0.22 with a QOC of 5.2/10, while SLXN trades at $4.91 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).